Infinium Pharmachem Ltd (INFINIUM) is currently trading at 286.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Infinium Pharmachem Limited specializes in the manufacturing of iodine-based pharmaceutical intermediates, catering to diverse industries such as pharmaceuticals, biotechnology, and specialty chemicals. The company is strategically expanding its iodine value chain by venturing into the contrast media segment, aiming for substantial revenue from sales beginning FY26, and targeting Rs 300 Cr in revenue in 3-5 years. A significant strategic joint venture with IBL Elements secures long-term iodine supply, enhancing control and cost effectiveness with a 30-year agreement for captive sourcing of ~120 MT/year. Infinium's recent strategic partnership with K Sakai & Company in Japan aims to tap into the unexplored iodine derivatives market across several sectors, expanding its global footprint. Despite a challenging market, Infinium achieved revenue growth with a 5-year CAGR of 32.1%, alongside a robust 5-year EBITDA CAGR of 43.39%, showcasing its operational efficiency.

Over the past 52 weeks, Infinium Pharmachem Ltd has traded between a low of ₹189.40 and a high of ₹324.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Infinium Pharmachem Ltd has a market capitalization of approximately 445.68. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Infinium Pharmachem Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.68 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 445.68 Cr, Infinium Pharmachem Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Infinium Pharmachem Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Infinium Pharmachem Ltd is 36.68. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.